← All trials
NCT02724046
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 22, 2017
- Primary completion
- May 30, 2017
- Completion date
- Dec 31, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- EpicentreLead sponsor
- EpicentreStudy director
- Medecins Sans FrontieresCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.